| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.06B | +52.8% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | — |
| Gross margin | 13.7% | Net margin -2.5% |
| Revenue Q/Q | -8.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.05B | 86.3% |
| R&D | ¥0.00B | 4.6% |
| SG&A | ¥0.01B | 14.2% |
| Tax & other | ¥-0.00B | -0.7% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
药易购 ・ 信测标准 ・ 秋田微 ・ 南极光 ・ 创识科技 ・ 易瑞生物 ・ 春晖智控 ・ 曼卡龙 ・ 恒而达 ・ 德必集团 ・ 冠中生态 ・ 奥雅股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies